Vianautis

ViaNautis is revolutionising cell and gene therapy with polyNaut® nanovesicles, its modular, disease-agnostic, non-viral delivery system, enabling precise, plug-and-play targeting to critical cell types in the CNS (across the blood-brain barrier), lung, and immune system. Delivering a full spectrum of genetic payloads, polyNaut® nanovesicles combine good tolerability and low immunogenicity with radically simplified manufacturing and long-term product stability. polyNaut® supports the potential for safe, redosable therapies with scalable, competitive manufacturing, making advanced cell and gene treatments accessible beyond specialist centres. ViaNautis is supported by blue chip investors including 4BIO Capital, BGF, UCB Ventures and Eli Lilly. Also backed by strategic partnerships with industry leaders, such as Eli Lilly and the Cystic Fibrosis Foundation, and validated by a board of sector pioneers, ViaNautis’s pipeline spans high-impact programmes in CNS, cystic fibrosis, and immunology, and addresses patient populations from tens of thousands to millions. Through its internal pipeline and collaborations, ViaNautis is poised to transform the future of cell and gene therapy, widening its disease scope and making it more affordable and accessible than ever before.